Brett Levinson, MD
Ophthalmology · Baltimore, MDNPI 1245267798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,480 of the $58,518 with a category attached, or 82.8%. Sun Pharmaceutical Industries Inc. accounts for 90.6% of it on its own, with 14 other manufacturers making up the rest. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $316.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$53K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- AbbVie$318
- Bausch & Lomb Americas Inc.$301
- Kala Pharmaceuticals, Inc.$287
- Johnson & Johnson Vision Care, Inc.$240
- plus $610 from 9 others
What the payments were for
- Consulting fees$3,6606%
- Speaking & faculty fees$48,48083%
- Travel & lodging$1,6223%
- Food & beverage$4,7108%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 127 | $52,999 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $3,762 |
| AbbVie(2 entities) | 10 | $318 |
| Bausch & Lomb Americas Inc. | 6 | $301 |
| Kala Pharmaceuticals, Inc. | 9 | $287 |
| Johnson & Johnson Vision Care, Inc. | 3 | $240 |
| Thea Pharma Inc. | 4 | $160 |
| Harrow Eye, LLC | 4 | $82 |
| Oyster Point Pharma, Inc. | 3 | $67 |
| Dompe US, Inc. | 3 | $62 |
| Coopervision Inc. | 3 | $60 |
| Novartis | 3 | $55 |
| Alcon | 2 | $53 |
| Biotissue Holdings Inc. | 3 | $50 |
| Lumenis, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,518 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 319 | $427,510 |
| XiidraLifitegrast | 94 | $104,409 |
| Cyclosporine | 131 | $58,723 |
| CequaCyclosporine | 34 | $46,276 |
| LumiganBimatoprost | 31 | $15,188 |
| Loteprednol Etabonate | 83 | $12,116 |
| Travatan ZTravoprost | 16 | $5,479 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 422 | $4,413 |
| Latanoprost | 301 | $4,338 |
| Travoprost | 20 | $3,123 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,385 |
| Dexamethasone Sodium Phosphate | 58 | $2,176 |
| Prednisolone Acetate | 67 | $2,059 |
| ValacyclovirValacyclovir Hcl | 29 | $1,955 |
| Doxycycline Hyclate | 62 | $1,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $318 | $442,698350 claims |
| Bausch & Lomb Americas Inc.Xiidra | $301 | $104,40994 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $52,999 | $46,27634 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $3,762 | $12,11683 claims |
| NovartisTravatan Z | $55 | $5,47916 claims |
| AlconSimbrinza | $53 | $2,38512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.